Oxford Biomedica PLC

Board/Management Information • Jun 22, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2709S

Oxford Biomedica PLC

22 June 2018

Confirmation of change of Auditor

London, UK - 22 June 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces that it has appointed KPMG LLP as the auditor to the Company as approved by the shareholders at the Company's Annual General Meeting held on 29 May 2018.

PricewaterhouseCoopers LLP has resigned as the Company's auditor and has confirmed to the Company that, in accordance with Section 519 of the Companies Act 2006, there are no circumstances in connection with its resignation which it considers need to be brought to the attention of the Company's members or creditors.

- Ends -

For further information, please contact:

Oxford BioMedica plc:                                                                Tel: +44 (0)1865 783 000

John Dawson,  Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Financial PR Enquiries:                                                             Tel: +44 (0)20 3709 5700

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal /

Oliver Manser / Laura Thornton

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPLLFILRVIFFIT